Biotech

All Articles

Genentech to finalize cancer immunology study division

.Genentech will definitely close its own cancer immunology analysis department, as well as system he...

Kezar falls strong tumor but to prove its worth in phase 1 trial

.Kezar Life Sciences is falling its own unpromising period 1 solid lump medication as the biotech go...

Acelyrin falls izokibep, lets go 3rd of personnel

.Regardless of izokibep maintaining its own newfound winning streak in the clinic, Acelyrin is actua...

Rivus' phase 2 obesity-related heart failure trial hits endpoint

.Rivus Pharmaceuticals has actually plumped up the prospects of its own fat-busting, muscle-sparing ...

Ovid halts preclinical job, IV course after soticlestat stop working

.Ovid Rehab actually disclosed final month that it was trimming back its headcount as the business g...

Eli Lilly opens up $700M nucleic acid R&ampD facility in Boston ma Port

.Eli Lilly has actually opened up a $700 thousand R&ampD center in the Boston Port, enhancing its ow...

Boundless Bio helps make 'reasonable' cutbacks 5 months after $100M IPO

.Just 5 months after getting a $100 million IPO, Vast Bio is actually already giving up some staff m...

Halda's $126M will certainly evolve 'hold and kill' lump medicines

.The initial phases of oncology R&ampD aren't except appealing brand-new modalities, and Halda Thera...

Lykos 'regrets' not disclosing study infractions with publisher

.Psychopharmacology has actually drawn three posts concerning midstage medical trial records analyzi...

Analysts go into Avidity's DMD succeed, showing subtleties in information

.Avidity Biosciences pleased clients along with phase 1/2 records in Duchenne muscle dystrophy (DMD)...